BSX Boston Scientific Corporation

Price (delayed)

$37.15

Market cap

$53.15B

P/E Ratio

12.99

Dividend/share

N/A

EPS

$2.86

Enterprise value

$60.96B

Sector: Healthcare
Industry: Medical Devices
Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment comprises of technologies or diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Highlights

BSX's quick ratio has surged by 168% year-on-year and by 108% since the previous quarter
The P/E is 87% below the 5-year quarterly average of 101.1 and 41% below the last 4 quarters average of 21.9
Boston Scientific's net income has surged by 185% YoY but it has decreased by 7% QoQ
The EPS has soared by 183% YoY but it has decreased by 7% from the previous quarter
Boston Scientific's gross profit has decreased by 9% QoQ and by 3.6% YoY
The revenue has decreased by 6% from the previous quarter

Key stats

What are the main financial stats of BSX
Market
Shares outstanding
1.43B
Market cap
$53.15B
Enterprise value
$60.96B
Valuations
Price to earnings (P/E)
12.99
Price to book (P/B)
3.33
Price to sales (P/S)
5.16
EV/EBIT
160.41
EV/EBITDA
43.82
EV/Sales
6
Earnings
Revenue
$10.16B
EBIT
$380M
EBITDA
$1.39B
Free cash flow
$1.02B
Per share
EPS
$2.86
Free cash flow per share
$0.72
Book value per share
$11.16
Revenue per share
$7.2
TBVPS
$9.61
Balance sheet
Total assets
$30.82B
Total liabilities
$15.21B
Debt
$9.53B
Equity
$15.62B
Working capital
$2.7B
Liquidity
Debt to equity
0.61
Current ratio
1.87
Quick ratio
1.02
Net debt/EBITDA
5.61
Margins
EBITDA margin
13.7%
Gross margin
68.2%
Net margin
39.2%
Operating margin
6.6%
Efficiency
Return on assets
13.5%
Return on equity
30%
Return on invested capital
2.2%
Return on capital employed
1.4%
Return on sales
3.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BSX stock price

How has the Boston Scientific stock price performed over time

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$10.16B
Gross profit
$6.93B
Operating income
$669M
Net income
$3.99B
Gross margin
68.2%
Net margin
39.2%
Boston Scientific's net income has surged by 185% YoY but it has decreased by 7% QoQ
Boston Scientific's net margin has surged by 182% YoY
BSX's operating margin has dropped by 59% year-on-year and by 37% since the previous quarter
Boston Scientific's operating income has plunged by 59% YoY and by 40% from the previous quarter

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
P/E
12.99
P/B
3.33
P/S
5.16
EV/EBIT
160.41
EV/EBITDA
43.82
EV/Sales
6
The EPS has soared by 183% YoY but it has decreased by 7% from the previous quarter
The P/E is 87% below the 5-year quarterly average of 101.1 and 41% below the last 4 quarters average of 21.9
The equity has soared by 66% YoY and by 13% from the previous quarter
The stock's price to book (P/B) is 33% less than its 5-year quarterly average of 5.0 and 21% less than its last 4 quarters average of 4.2
BSX's P/S is 15% above its 5-year quarterly average of 4.5
The revenue has decreased by 6% from the previous quarter

Efficiency

How efficient is Boston Scientific business performance
The return on assets has surged by 118% year-on-year but it has declined by 12% since the previous quarter
The return on equity has surged by 91% year-on-year but it has declined by 18% since the previous quarter
BSX's ROIC has plunged by 86% YoY and by 49% from the previous quarter
The ROS has plunged by 78% YoY and by 43% from the previous quarter

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 103% more than its total liabilities
BSX's quick ratio has surged by 168% year-on-year and by 108% since the previous quarter
BSX's current ratio has surged by 55% since the previous quarter and by 43% year-on-year
Boston Scientific's debt is 39% lower than its equity
The equity has soared by 66% YoY and by 13% from the previous quarter
Boston Scientific's debt to equity has decreased by 40% YoY and by 19% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.